“…Furthermore, TMCs were reported to modulate autophagy in response to several stimuli ranging from oxidative stress to mechanical stretch [ 58 , 59 , 60 ]. Main evidence for this is: (i) a decrease in autophagy markers, such as LC3B-II, in TMCs isolated from glaucomatous subjects along with a reduced lysosome basification [ 18 , 59 ]; (ii) a dysregulation of autophagy upon chronic oxidative stress exposure in cultivated TMCs [ 59 ]; (iii) the role of autophagy in TGF-β-mediated TM stiffness [ 61 ]; (iv) autophagy is a central pathway in retina neurodegeneration during ageing [ 62 ]; (v) a defective autophagy flux in the DBA/J2 mouse, a glaucoma murine model characterized by a spontaneous development of IOP [ 63 ]; (vi) the protective effect of rapamycin, an autophagy inducer, against RGCs apoptosis and IOP elevation in a rat model of glaucoma [ 64 ]. Very recently, a dysregulation of autophagy, based on a reduced content of LC3B-II and Beclin-1, has been reported in TMCs of DBA/J2 mouse treated with GCs and, further, a protective role of rapamycin, again, in TMCs homeostasis and TM remodeling, was uncovered [ 65 , 66 ].…”